Format

Send to

Choose Destination
J Neurooncol. 2017 Jun;133(2):223-235. doi: 10.1007/s11060-017-2446-4. Epub 2017 Apr 22.

Dendritic cell based vaccination strategy: an evolving paradigm.

Author information

1
Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, IN, USA.
2
Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, IN, USA. mdey@iu.edu.
3
Indiana University Purdue University Indianapolis (IUPUI), 320 W 15th Street, Neuroscience Building NB400A, Indianapolis, IN, 46202, USA. mdey@iu.edu.

Abstract

Malignant gliomas (MG), tumors of glial origin, are the most commonly diagnosed primary intracranial malignancies in adults. Currently available treatments have provided only modest improvements in overall survival and remain limited by inevitable local recurrence, necessitating exploration of novel therapies. Among approaches being investigated, one of the leading contenders is immunotherapy, which aims to modulate immune pathways to stimulate the selective destruction of malignant cells. Dendritic cells (DCs) are potent initiators of adaptive immune responses and therefore crucial players in the development and success of immunotherapy. Clinical trials of various DC-based vaccinations have demonstrated the induction of anti-tumor immune responses and prolonged survival in the setting of many cancers. In this review, we summarize current literature regarding DCs and their role in the tumor microenvironment, their application and current clinical use in immunotherapy, current challenges limiting their efficacy in anti-cancer therapy, and future avenues for developing successful anti-tumor DC-based vaccines.

KEYWORDS:

Dendritic cell based vaccine; Glioblastoma; Immunotherapy; Malignant glioma

PMID:
28434112
PMCID:
PMC5532060
DOI:
10.1007/s11060-017-2446-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center